4D Molecular Therapeutics (NASDAQ:FDMT) Stock Keeps Buy Rating at HC Wainwright

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They presently have a $36.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 185.26% from the company’s current price.

A number of other research analysts have also recently commented on the stock. Chardan Capital reduced their target price on shares of 4D Molecular Therapeutics from $26.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, October 6th. The Goldman Sachs Group restated a “buy” rating and set a $32.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Thursday, October 15th. B. Riley Financial reaffirmed a “buy” rating on shares of 4D Molecular Therapeutics in a research report on Monday, August 17th. Finally, Bank of America increased their target price on 4D Molecular Therapeutics from $29.00 to $33.00 and gave the company a “buy” rating in a research note on Tuesday, September 29th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $28.90.

4D Molecular Therapeutics Stock Down 3.7%

Shares of NASDAQ:FDMT opened at $12.62 on Thursday. 4D Molecular Therapeutics has a twelve month low of $6.96 and a twelve month high of $16.93. The company has a market capitalization of $697.13 million, a PE ratio of -4.80 and a beta of 2.75. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05. The firm has a 50 day simple moving average of $14.07 and a 200-day simple moving average of $11.60.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The business had revenue of $3.78 million during the quarter, compared to analyst estimates of $3.62 million. On average, equities analysts predict that 4D Molecular Therapeutics will post -4.14 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider David Kirn sold 58,333 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $12.92, for a total transaction of $753,662.36. Following the completion of the sale, the insider directly owned 709,153 shares in the company, valued at approximately $9,162,256.76. This trade represents a 7.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 136,205 shares of company stock worth $1,780,316. Insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Toth Financial Advisory Corp acquired a new stake in shares of 4D Molecular Therapeutics in the third quarter valued at about $29,000. Opaleye Management Inc. lifted its position in shares of 4D Molecular Therapeutics by 197.8% during the 2nd quarter. Opaleye Management Inc. now owns 334,437 shares of the company’s stock worth $4,448,000 after purchasing an additional 222,146 shares during the last quarter. Engineers Gate Manager LP lifted its position in shares of 4D Molecular Therapeutics by 132.0% during the 2nd quarter. Engineers Gate Manager LP now owns 68,206 shares of the company’s stock worth $907,000 after purchasing an additional 38,806 shares during the last quarter. AXQ Capital LP acquired a new position in shares of 4D Molecular Therapeutics during the 2nd quarter worth about $186,000. Finally, Headlands Technologies LLC boosted its stake in 4D Molecular Therapeutics by 20.6% during the 2nd quarter. Headlands Technologies LLC now owns 19,238 shares of the company’s stock valued at $256,000 after purchasing an additional 3,282 shares during the period. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to design adeno-associated virus (AAV) vectors intended to deliver genetic medicines to specific tissues and organs.

Its pipeline has focused primarily on ophthalmology and pulmonology. Key investigational programs have included 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema, and 4D-710, an inhaled gene therapy designed to address the underlying cause of cystic fibrosis in patients who cannot benefit from existing CFTR modulator treatments.